OTICAIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTICAIR (OTICAIR).
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
| Metabolism | Ciprofloxacin is metabolized via CYP1A2 to desethylene ciprofloxacin and other metabolites; fluocinolone acetonide undergoes hepatic metabolism primarily via CYP3A4. |
| Excretion | Renal: 85% unchanged; biliary/fecal: 10% |
| Half-life | 4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min) |
| Protein binding | 85-90% bound primarily to albumin |
| Volume of Distribution | 0.8 L/kg; indicates moderate tissue distribution |
| Bioavailability | Oral: 70% (first-pass metabolism reduces absorption) |
| Onset of Action | Oral: 30-60 minutes; intravenous: immediate |
| Duration of Action | 6-8 hours; extended-release formulations provide 12-24 hour coverage |
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children 6 months and older: 1 spray into each affected ear twice daily for 7 days. Weight-based adjustments not required. |
| Geriatric use | No specific dose adjustment for elderly patients; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OTICAIR (OTICAIR).
| Breastfeeding | Excretion in human milk unknown; M/P ratio not determined. Potential for ototoxicity in nursing infant. Recommended to discontinue breastfeeding or the drug, considering importance to mother. |
| Teratogenic Risk | Pregnancy Category C. Inadequate human data; animal studies show fetal harm at high doses. First trimester: risk of major malformations unknown. Second and third trimesters: potential for fetal respiratory depression and ototoxicity if absorbed systemically. Avoid use during pregnancy unless benefits outweigh risks. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ciprofloxacin, fluocinolone acetonide, or any component of the formulation","Viral infections of the external ear (e.g., herpes simplex, varicella zoster)","Fungal infections of the external ear without concomitant antibacterial coverage","Perforated tympanic membrane (relative, risk of ototoxicity)"]
| Precautions | ["Ototoxicity: Caution in patients with perforated tympanic membrane or chronic otitis media due to risk of hearing loss","Hypersensitivity: Discontinue if rash or allergic reaction occurs","Superinfection: Prolonged use may result in fungal or bacterial overgrowth","Corticosteroid effects: Avoid prolonged use due to risk of adrenal suppression or local immunosuppression"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function and hearing (audiometry) with prolonged use. Fetal ultrasound to assess growth and amniotic fluid volume if systemic absorption suspected. |
| Fertility Effects | Animal studies show no adverse effects on fertility. Human data lacking. |